BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

規制と法律 · 2000/10/171 分で読めます

Prospective Grant of Exclusive License: Insulin Producing Cells Differentiated from Non-Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof

ローカル自動翻訳 · 情報源の原言語

概要

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: PCT Patent Application Serial Number PCT/US99/180899 (PHS Ref. E-151- 97/1) entitled "Insulin Producing Cells Differentiated from Non- Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof" filed on August 18, 1999, claiming priority of August 10, 1998, to Amylin Pharmaceuticals, Inc., having a place of business in San Diego, CA. The patent rights in this invention have been assigned to the United States America.

情報源の原言語: Federal Register — All Documents原文の発表を開く →

関連インサイト

ビジネスインサイト →